Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Personalized Neoantigen Cancer Vaccine (Colorectal/Pancreatic) Market: MSI-H Biomarker-Directed Demand, Adjuvant Treatment Growth, and AI-Based Neoantigen Identification Adoption to Drive Exceptional Market Expansion Through 2035

The global Personalized Neoantigen Cancer Vaccine (Colorectal/Pancreatic) Market is projected to expand at an exceptional CAGR of 27.7% through 2035, driven by sustained demand for microsatellite instability-directed treatment approaches, growing adoption of personalized vaccines in the adjuvant treatment setting following resection, and continued use of AI-based neoantigen identification methodology. Given data limitations in the underlying source figures for this specific sub-segment, this brief presents the CAGR-based growth outlook without specific market size figures. The market comprises commercially available, regulatory-stage, and clinical-pipeline personalized neoantigen vaccine products specifically applied across colorectal and pancreatic cancer treatment.

The market’s exceptional 27.7% CAGR reflects growing clinical recognition of colorectal and pancreatic cancer as viable indications for personalized neoantigen vaccination despite their traditionally lower mutational burden relative to melanoma, generating structured demand from comprehensive cancer centers well above typical specialty biopharmaceutical growth rates. Sustained clinical evidence differentiating microsatellite instability-high from microsatellite stable tumor biology continues to reinforce procurement volumes, while adjuvant treatment following resection of pancreatic ductal adenocarcinoma represents a distinct and increasingly important clinical setting among vaccine developers. Coverage extending across multiple neoantigen identification methods, disease subtypes, and treatment settings underscores the breadth of clinical and manufacturing infrastructure now supporting this category.

Executive Snapshot

How does MSI-H biomarker-directed demand drive market growth?
Oncology centers increasingly differentiate treatment approaches between microsatellite instability-high and microsatellite stable colorectal tumors, given the substantially higher mutational burden and neoantigen availability in MSI-H disease. This biomarker-directed treatment approach is establishing itself as a primary driver of clinical activity, with procurement associated with MSI-H-directed vaccination expected to outpace growth across the wider colorectal cancer therapeutics sector.

What role does adjuvant treatment growth play in market expansion?
Oncology centers increasingly administer personalized neoantigen vaccines in the adjuvant setting following surgical resection of pancreatic ductal adenocarcinoma and locally advanced colorectal cancer, sustaining structured demand above conventional advanced-disease treatment baselines. Continued clinical evidence supporting early intervention following resection is generating demand that increasingly exceeds levels attributable to later-line treatment settings alone.

How does AI-based neoantigen identification adoption sustain market growth?
Vaccine developers increasingly rely on artificial intelligence and machine learning-based neoantigen prediction methods to identify immunogenic mutations in tumor types with comparatively lower mutational burden, sustaining structured demand from technology-forward developer accounts pursuing differentiated vaccine design methodology.

What is driving demand for personalized vaccines in metastatic pancreatic cancer applications?
Developers pursuing personalized vaccine candidates for metastatic and locally advanced pancreatic cancer continue to extend treatment applications into this historically difficult-to-treat indication, generating incremental demand among clinical-stage biopharmaceutical developers pursuing broader patient eligibility.

How does combination therapy with chemotherapy sustain the market?
Oncology centers increasingly pair personalized neoantigen vaccines with standard chemotherapy regimens in colorectal and pancreatic cancer treatment protocols, sustaining structured demand from combination-therapy accounts pursuing enhanced clinical outcomes.

Which colorectal/pancreatic cancer vaccine market segments are growing fastest?
The fastest-growing segments include MSI-H-directed treatment approaches, adjuvant treatment settings following pancreatic ductal adenocarcinoma resection, AI and machine learning-based neoantigen prediction methods, and multi-neoantigen vaccine panel designs.

Request Sample
Speak with an Analyst
Download TOC

Market Dynamics: Personalized Neoantigen Cancer Vaccine (Colorectal/Pancreatic) Market

  • Pancreatic ductal adenocarcinoma sustaining a leading share of clinical development activity: Adjuvant treatment following resection of this historically difficult-to-treat cancer type continues to anchor a substantial share of overall clinical activity.
  • MSI-H colorectal cancer sustaining structured demand above microsatellite stable disease: Higher mutational burden and neoantigen availability in MSI-H tumors continues to direct developer and treatment center focus toward this biomarker-defined subgroup.
  • Adjuvant therapy following surgical resection sustaining structured early-intervention demand: Post-surgical vaccine administration continues to represent a growing share of overall clinical activity across both colorectal and pancreatic cancer indications.
  • AI and machine learning-based neoantigen identification sustaining structured methodology-driven demand growth: Improving prediction accuracy continues to direct developer investment toward AI-based selection methods, particularly relevant given the comparatively lower mutational burden in these tumor types.
  • Combination therapy with chemotherapy sustaining demand above vaccine monotherapy protocols: Growing clinical evidence supporting combined vaccine and chemotherapy administration continues to direct treatment center demand toward combination regimens.
  • Metastatic pancreatic cancer applications sustaining structured advanced-disease demand growth: Developers extending vaccine candidates into metastatic disease settings continue to generate incremental demand from clinical-stage biopharmaceutical accounts.

Market Segmentation: Personalized Neoantigen Cancer Vaccine (Colorectal/Pancreatic) Market

By Platform
  • mRNA-Based Vaccines
  • Peptide-Based Vaccines
  • DNA-Based Vaccines
  • Dendritic Cell-Based Vaccines
  • Viral Vector-Based Vaccines
  • Other Emerging Platforms
By Identification Method
  • Whole-Exome Sequencing (WES)
  • Whole-Genome Sequencing (WGS)
  • RNA Sequencing
  • WES + RNA Sequencing
  • Multi-Omics Analysis
  • AI / Machine Learning-Based Neoantigen Prediction
  • Other Identification Methods
By Cancer Type
  • Colorectal Cancer
    • Microsatellite Instability-High (MSI-H) / dMMR
    • Microsatellite Stable (MSS) / pMMR
    • Metastatic Colorectal Cancer
    • Locally Advanced Colorectal Cancer
  • Pancreatic Cancer
    • Pancreatic Ductal Adenocarcinoma (PDAC)
    • Resectable Pancreatic Cancer
    • Locally Advanced Pancreatic Cancer
    • Metastatic Pancreatic Cancer
By Treatment Approach
  • Monotherapy
  • Combination Therapy
By Treatment Setting
  • Adjuvant Therapy
  • Neoadjuvant Therapy
  • Maintenance Therapy
  • Treatment of Advanced Disease
  • Treatment of Recurrent / Relapsed Disease
By Disease Stage
  • Early-Stage Cancer
  • Locally Advanced Cancer
  • Metastatic Cancer
  • Recurrent / Relapsed Cancer
  • Advanced / Unresectable Cancer
By Route of Administration
  • Intramuscular
  • Intravenous
  • Subcutaneous
  • Intradermal
  • Other Routes
By Patient Type
  • Adult Patients
  • Geriatric Patients
  • Pediatric Patients
By Distribution Channel
  • Direct Sales
  • Hospital Pharmacies
  • Specialty Pharmacies
  • Specialty Oncology Distributors
  • Other Channels
By Product Development Stage
  • Commercially Available Products
  • Phase III Products
  • Phase II Products
  • Phase I Products
  • Preclinical Products
By Manufacturing Model
  • Centralized Manufacturing
  • Decentralized Manufacturing
  • In-House Manufacturing
  • Contract Manufacturing
  • Hybrid Manufacturing
By End User
  • Comprehensive Cancer Centers
  • Hospitals
  • Specialty Oncology Clinics
  • Academic Medical Centers
  • Cancer Research Institutes
  • Other Healthcare Institutions
By Geography
  • North America: United States, Canada, and Mexico
  • Europe:  Germany, U.K., France, Italy, Spain, Russia, Benelux, Nordics, and Rest of Europe
  • Asia Pacific: China, Japan, India, South Korea, Australia, New Zealand, Taiwan, South East Asia, and Rest of Asia Pacific
  • Latin America: Brazil, Argentina, Columbia, Chile, Peru, and Rest of Latin America
  • Middle East: Saudi Arabia, United Arab Emirates, Oman, Qatar, and Rest of Middle East
  • Africa: Nigeria, Egypt, Ethiopia, South Africa, and Rest of Africa

Key Growth Drivers: Personalized Neoantigen Cancer Vaccine (Colorectal/Pancreatic) Market

  1. Growing biomarker-directed treatment approaches driving MSI-H-specific vaccine demand: Higher neoantigen availability in MSI-H colorectal tumors continues to support structured vaccine demand above microsatellite stable disease baseline.
  2. Sustained clinical evidence supporting resection-adjacent treatment driving adjuvant setting adoption: Post-surgical vaccine administration following pancreatic and colorectal cancer resection continues to expand the addressable patient population.
  3. Advancing AI-based prediction algorithms supporting neoantigen identification in lower-mutational-burden tumors: Improving accuracy in identifying immunogenic mutations continues to direct developer investment toward AI-driven vaccine design methodology.
  4. Continued extension into metastatic pancreatic cancer broadening addressable demand: Developers pursuing advanced disease indications continue to generate incremental demand from clinical-stage biopharmaceutical accounts.
  5. Growing clinical evidence supporting chemotherapy combination protocols sustaining demand: Combined vaccine and chemotherapy administration continues to direct treatment center demand toward combination regimens.
  6. Maturing regulatory pipelines supporting an approaching wave of commercial launches: A growing pipeline of late-stage candidates continues to focus treatment center and payer attention on the category’s next phase of expansion.

Regional Outlook: Personalized Neoantigen Cancer Vaccine (Colorectal/Pancreatic) Market

  • North America: The United States accounts for the largest share of regional demand, supported by extensive cancer center infrastructure, broad payer coverage, and leading clinical trial activity in colorectal and pancreatic cancer vaccine development; regional cancer centers continue to expand sequencing and vaccine manufacturing capacity to accommodate this demand.
  • Europe: Germany, the United Kingdom, and France anchor regional demand, supported by growing specialized oncology center capacity and consistent clinical trial activity; this demand base is expected to remain broadly stable through the forecast period.
  • Asia-Pacific: Japan, China, and South Korea represent some of the fastest-growing regional markets given high colorectal cancer incidence rates and expanding biopharmaceutical clinical trial activity; regional cancer centers continue to invest in the specialized infrastructure required to support this expansion.
  • Latin America: Brazil and Mexico represent an emerging regional demand base as specialized cancer centers begin to participate in personalized colorectal and pancreatic cancer vaccine clinical trials; this segment is expected to follow a steady, if more gradual, growth trajectory through 2035.

Competitive Landscape: Personalized Neoantigen Cancer Vaccine (Colorectal/Pancreatic) Market

Key Players
Moderna, Inc., Merck & Co., Inc., BioNTech SE, Genentech, Inc. (Roche), Gritstone bio, Inc., Nouscom AG, Evaxion Biotech A/S, Transgene S.A., Geneos Therapeutics, Inc., Genocea Biosciences, Inc., Ose Immunotherapeutics S.A., Personalis, Inc., NEC Corporation, PGV-Elicio Therapeutics, Inc.

  • BioNTech SE [March 2026] — confirmed continued clinical progress for its individualized mRNA vaccine candidate in resected pancreatic ductal adenocarcinoma, with the company noting sustained investigator interest in adjuvant treatment applications.
  • Genentech, Inc. (Roche) [December 2025] — reported continued clinical collaboration on individualized neoantigen therapy in colorectal cancer, with the company noting expanding trial enrollment among MSI-H biomarker-selected patients.
  • Elicio Therapeutics, Inc. [September 2025] — confirmed continued clinical development of its lymph node-targeted amphiphile vaccine platform in pancreatic and colorectal cancer, with the company reporting structured investor interest in its neoantigen delivery technology.

Consultant POV

The Personalized Neoantigen Cancer Vaccine (Colorectal/Pancreatic) Market’s exceptional 27.7% CAGR outlook through 2035 is anchored in sustained MSI-H biomarker-directed demand, growing adjuvant treatment activity, and continued AI-based neoantigen identification adoption. Sustained clinical and manufacturing investment from companies including BioNTech SE, Genentech, Inc. (Roche), and Elicio Therapeutics, Inc. confirms the Personalized Neoantigen Cancer Vaccine (Colorectal/Pancreatic) Market will sustain exceptional growth through 2035.

Request Sample
Speak with an Analyst
Download TOC

About Constancy Researchers Private Limited

Constancy Researchers is a global market intelligence and strategic advisory firm helping organizations navigate complex markets and make high-impact decisions with confidence. In an environment defined by rapid technological change, shifting demand patterns, and evolving competitive dynamics, we provide clarity where it matters most—at the point of decision-making. By combining deep industry understanding, rigorous analytics, and structured thinking, we enable leadership teams to identify opportunities, mitigate risks, and build strategies that drive sustainable growth.

More Press Releases

Speak with an Analyst

    Download TOC

      Request a Sample Report